KIT and Kaposi's sarcoma: Given that activation of platelet-derived growth factor (PDGF) and tyrosine kinase (TK) receptor c-kit has been demonstrated to have a role in KS pathogenesis bothin vitro andin vivo, imatinib, a selective inhibitor of the TK Abl and c-kit, has been tested in HIV-KS with promising results40.